PMC:4460872 / 39319-41369
Annnotations
PubTator4TogoVar
{"project":"PubTator4TogoVar","denotations":[{"id":"9907","span":{"begin":2006,"end":2015},"obj":"SNP"},{"id":"9899","span":{"begin":1951,"end":1960},"obj":"SNP"},{"id":"9900","span":{"begin":1918,"end":1927},"obj":"SNP"},{"id":"9901","span":{"begin":1888,"end":1897},"obj":"SNP"},{"id":"9902","span":{"begin":1851,"end":1861},"obj":"SNP"}],"attributes":[{"id":"A9907","pred":"resolved_to","subj":"9907","obj":"tmVar:rs3910384;VariantGroup:4;CorrespondingGene:7465;RS#:3910384;CorrespondingSpecies:9606"},{"id":"A9899","pred":"resolved_to","subj":"9899","obj":"tmVar:rs1049403;VariantGroup:3;CorrespondingGene:7465;RS#:1049403;CorrespondingSpecies:9606"},{"id":"A9900","pred":"resolved_to","subj":"9900","obj":"tmVar:rs4370932;VariantGroup:0;CorrespondingGene:7465;RS#:4370932;CorrespondingSpecies:9606"},{"id":"A9901","pred":"resolved_to","subj":"9901","obj":"tmVar:rs3910384;VariantGroup:4;CorrespondingGene:7465;RS#:3910384;CorrespondingSpecies:9606"},{"id":"A9902","pred":"resolved_to","subj":"9902","obj":"tmVar:rs3829254;VariantGroup:7;RS#:3829254"}],"text":"Table 3 Cox’s regression analysis of prognostic factors for overall survival in the 152 NSCLC patients treated with platinum-gemcitabine regimen.\n Univariate Multivariate\nmOS(95%CI) HR (95% CI) p HR (95% CI) p\nAge\n\u003c60 19.5(16.3–22.8) \n≥60 16.1(12.3–20.0) 1.36(0.92–2.01) 0.125 1.34(0.90–2.01) 0.155\nGender:\nMale 15.5(12.2–18.8) \nFemale 20.0(15.3–24.7) 0.73(0.49–1.08) 0.118 0.81(0.51–1.27) 0.351\nSmoking history:\nNever smoker 19.0(15.6–22.5) \nEver Smoker 16.1(11.9–20.4) 1.07(0.73–1.58) 0.724 0.75(0.42–1.32) 0.317\nECOG PS:\n1 18.4(15.4–21.4) \n2 17.5(14.4–20.6) 1.68(0.85–3.34) 0.139 1.19(0.57–2.49) 0.641\nClinical stage\nIIIa 19.0 \nIIIb 16.8(12.2–21.4) 1.18(0.87–1.61) 0.294 1.27(0.90–1.79) 0.174\nIV 17.8(14.6–21.1) \nHistology 0.05* 0.037*\nadenocarcinoma 19.5(16.1–23.0) 1 R \nsquamous cell 13.7(9.4–18.1) 1.50(0.92–2.45) 0.107 1.60(0.96–2.65) 0.069\nadenosquamous 12.7(0–30.1) 3.98(1.23–12.87) 0.021 4.11(1.27–13.31) 0.018*\nothers 18.8(12.3–25.3) 1.50(0.77–2.91) 0.235 1.49(0.74–2.99) 0.262\nrs3829254 recessive \nA/A 19.5(14.4–24.7) \nAG+GG 14.7(10.7–18.7) 1.61(1.09–2.38) 0.018* 1.15(0.67–1.98) 0.603\nrs3910384 dominant \nG/G 28.2(20.5–35.9) 0.43(0.28–0.65) 7.6E-5* 0.42(0.27–0.64) 6.9E-5*\nAA+AG 14.7(12.8–16.6) \nrs4370932 additive \n NA NA 0.012* 1.04(0.51–2.13) 0.917\nrs1049403 recessive \nA/A 19.5(14.4–24.7) \nAG+GG 14.4(12.6–16.2) 1.62(1.10–2.39) 0.015* 0.82(0.27–2.50) 0.726\n*p \u003c 0.05. Abbrev.: mOS (months): median overall survival, HR: hazard ratio, NA: Not available, R: Reference. Variables used in the multivariate analysis: Age, Gender, smoking history, clinical stage, histology, the rs3829254 recessive model, the rs3910384 dominant model, the rs4370932 additive model and the rs1049403 recessive model."}
PubTatorOnTogoVar
{"project":"PubTatorOnTogoVar","denotations":[{"id":"7375","span":{"begin":1951,"end":1960},"obj":"SNP"},{"id":"7376","span":{"begin":1918,"end":1927},"obj":"SNP"},{"id":"7377","span":{"begin":1888,"end":1897},"obj":"SNP"},{"id":"7378","span":{"begin":1851,"end":1861},"obj":"SNP"},{"id":"7383","span":{"begin":2006,"end":2015},"obj":"SNP"},{"id":"T1","span":{"begin":2006,"end":2015},"obj":"SNP"},{"id":"T1","span":{"begin":1951,"end":1960},"obj":"SNP"},{"id":"T2","span":{"begin":1918,"end":1927},"obj":"SNP"},{"id":"T3","span":{"begin":1888,"end":1897},"obj":"SNP"},{"id":"T4","span":{"begin":1851,"end":1861},"obj":"SNP"}],"attributes":[{"id":"A7375","pred":"resolved_to","subj":"7375","obj":"tmVar:rs1049403;VariantGroup:3;CorrespondingGene:7465;RS#:1049403;CorrespondingSpecies:9606"},{"id":"A7376","pred":"resolved_to","subj":"7376","obj":"tmVar:rs4370932;VariantGroup:0;CorrespondingGene:7465;RS#:4370932;CorrespondingSpecies:9606"},{"id":"A7377","pred":"resolved_to","subj":"7377","obj":"tmVar:rs3910384;VariantGroup:4;CorrespondingGene:7465;RS#:3910384;CorrespondingSpecies:9606"},{"id":"A7378","pred":"resolved_to","subj":"7378","obj":"tmVar:rs3829254;VariantGroup:7;RS#:3829254"},{"id":"A7383","pred":"resolved_to","subj":"7383","obj":"tmVar:rs3910384;VariantGroup:4;CorrespondingGene:7465;RS#:3910384;CorrespondingSpecies:9606"}],"text":"Table 3 Cox’s regression analysis of prognostic factors for overall survival in the 152 NSCLC patients treated with platinum-gemcitabine regimen.\n Univariate Multivariate\nmOS(95%CI) HR (95% CI) p HR (95% CI) p\nAge\n\u003c60 19.5(16.3–22.8) \n≥60 16.1(12.3–20.0) 1.36(0.92–2.01) 0.125 1.34(0.90–2.01) 0.155\nGender:\nMale 15.5(12.2–18.8) \nFemale 20.0(15.3–24.7) 0.73(0.49–1.08) 0.118 0.81(0.51–1.27) 0.351\nSmoking history:\nNever smoker 19.0(15.6–22.5) \nEver Smoker 16.1(11.9–20.4) 1.07(0.73–1.58) 0.724 0.75(0.42–1.32) 0.317\nECOG PS:\n1 18.4(15.4–21.4) \n2 17.5(14.4–20.6) 1.68(0.85–3.34) 0.139 1.19(0.57–2.49) 0.641\nClinical stage\nIIIa 19.0 \nIIIb 16.8(12.2–21.4) 1.18(0.87–1.61) 0.294 1.27(0.90–1.79) 0.174\nIV 17.8(14.6–21.1) \nHistology 0.05* 0.037*\nadenocarcinoma 19.5(16.1–23.0) 1 R \nsquamous cell 13.7(9.4–18.1) 1.50(0.92–2.45) 0.107 1.60(0.96–2.65) 0.069\nadenosquamous 12.7(0–30.1) 3.98(1.23–12.87) 0.021 4.11(1.27–13.31) 0.018*\nothers 18.8(12.3–25.3) 1.50(0.77–2.91) 0.235 1.49(0.74–2.99) 0.262\nrs3829254 recessive \nA/A 19.5(14.4–24.7) \nAG+GG 14.7(10.7–18.7) 1.61(1.09–2.38) 0.018* 1.15(0.67–1.98) 0.603\nrs3910384 dominant \nG/G 28.2(20.5–35.9) 0.43(0.28–0.65) 7.6E-5* 0.42(0.27–0.64) 6.9E-5*\nAA+AG 14.7(12.8–16.6) \nrs4370932 additive \n NA NA 0.012* 1.04(0.51–2.13) 0.917\nrs1049403 recessive \nA/A 19.5(14.4–24.7) \nAG+GG 14.4(12.6–16.2) 1.62(1.10–2.39) 0.015* 0.82(0.27–2.50) 0.726\n*p \u003c 0.05. Abbrev.: mOS (months): median overall survival, HR: hazard ratio, NA: Not available, R: Reference. Variables used in the multivariate analysis: Age, Gender, smoking history, clinical stage, histology, the rs3829254 recessive model, the rs3910384 dominant model, the rs4370932 additive model and the rs1049403 recessive model."}